Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 6 results

ea0089t7 | Trials In Progress | NANETS2022

Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

Singh, MD Simron , Capdevila, MD, PhD Jaume , Ang Chan, MD Jennifer , de Herder, MD Wouter , Ferone, MD, PhD Diego , Halperin, MD Daniel , Mailman, MBA Josh , Hellstrom, MSc Lisa , Svedberg, MSc, MBA Agneta , Tiberg, PhD Fredrik

Background: Somatostatin analogues (SSAs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. Yet, disease progression may occur despite standard-dose SSA treatment, requiring more aggressive and toxic therapies. Retrospective/non-randomized data suggest higher-dose SSAs may benefit patients with GEP-NET who do not respond to standard-dose treatment a...
0 shares

ea0089c6 | Clinical – Chemo/SSA/Biologics | NANETS2022

An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Eads, MD Jennifer R. , Das, MD Satya , Li, MD Daneng , Mohamed, MD Amr , Tucci, MBS, CCRP Christopher , Nanda, MS Shivani , Kauh, MD, FACP John S. , Kania, MD, MBA Marek K. , Dasari, MD Arvind

Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...
0 shares

ea0089c38 | Clinical – Surgery/Applied Pathology | NANETS2022

Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

Concors, MD Seth J , Tzeng, MD Ching-Wei D , Ikoma MD Naruhiko , Kim MD Michael , Cao, MD Hop Tran , Lee, MD Jeffery E , Katz, MD Matthew HG , Maxwell, MD, MBA Jessica E

Background: Neuroendocrine tumors (NETs) are increasing in incidence and prevalence. Small intestine, rectum, pancreas and appendix are the most common enteric sites of NETs, and when identified early, surgical resection can be curative. We hypothesized that observed increases in incidence and prevalence of NETs are primarily driven by earlier detection of loco-regional tumors. In turn, increases in incidence of early-stage tumors is associated with increases in resection and ...
0 shares

ea0089c21 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

Coston, MD Tucker W. , Mahadevia, MBBS Himil J. , Plante, MD Marie M. , Accurso, MD Joseph M. , Sharma, MD, MBA Akash , Johnson, MD, PhD Geoffrey B. , Ashman, MD, PhD Jonathan B. , Tuba Kendi, MD Ayse , Bassam Sonbol, MD Mohamad , Hobday, MD Timothy J. , Halfdanarson, MD Thorvardur R. , Starr, DO Jason S.

Background: Tumors of neuroendocrine origin are a rare, heterogenous group of neoplasms. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status, and by grade (Ki-67 expression and/or mitotic rate), with significant prognostic variability accordingly. These tumors frequently metastasize to bone, with reported incidence between 6-12% by older SSTR imaging. Our study evaluates patients with well-differentiated tumors of neuroendocrine origin to ...
0 shares

ea0098b26 | Basic Science | NANETS2023

Cancer testis antigen and interleukin expression correlates with survival in small bowel neuroendocrine tumors

David Seo MD Y. , Witt MD, MAS Russell G. , Lazcano MD Rossana , MD Samuel Cass , Hudgens Courtney , Wani Khalida , Chelvanambi PhD Manoj , Johnson MS Sarah , Hernandez MD Sharia D. , Halperin MD Daniel M. , Lazar MD, PhD Alexander J. , Wargo MD, MMSc Jennifer A. , Estrella MD Jeannelyn S. , Maxwell MD, MBA Jessica E.

Background: Patients with small bowel neuroendocrine tumors (SBNETs) frequently present with metastatic disease, and unfortunately, the range and efficacy of available therapies is limited. Immunotherapeutic checkpoint inhibitors have demonstrated benefit in other malignancies and may also play a role in SBNETs, although relatively little is known about the immune infiltrate in these tumors. Toward a goal of developing novel immunomodulatory strategies, we sought to evaluate t...
0 shares

ea0098c43 | Clinical – Surgery/Applied Pathology | NANETS2023

Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection

Zhang, MD Chi , Gudmundsdottir, MD Hallbera , Takahashi, MD, PhD Hiroaki , Day, MS Courtney , Glasgow, MHA Amy , Wasif, MD, MPH Nabil , Starlinger, MD Patrick , Warner, MD Susanne , Grotz, MD Travis , Smoot, MD Rory , Truty, MD Mark , Cleary, MD Sean , Kendrick, MD Michael , Nagorney, MD David , Navin, MB, BCh Patrick , Halfdanarson, MD Thorvardur R. , Thiels, DO, MBA Cornelius

Background: Small bowel neuroendocrine tumors (sbNETs) incidence is on the rise. Given that sbNETS are often multifocal with high risk of regional nodal metastasis, open resection with lymphadenectomy is the gold standard approach as it offers manual palpation of the entire small bowel. We evaluated the accuracy of preoperative DOTATATE PET/CT in estimating the number of lesions and the presence of nodal disease compared to postoperative pathology findings. We hypothesize that...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more